AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02069418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG-TEP
Description: Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
Study NCT01337271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBT- PSV
Description: An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
Study NCT01337271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBT- PSV
Description: An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
Study NCT01337271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBT - NAVA
Description: An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
Study NCT00896454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: 120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
Study NCT03927872 — intervention group
Intervention type: OTHER
Intervention: blood biomarkers
Description: assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome
Study NCT02400307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: 75 mg tablet administered orally
Study NCT03088137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa (Gonal-f)
Description: Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
Study NCT03088137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa (Primapur)
Description: Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
Study NCT03248440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-131 1.5% TDS
Description: SUN-131 1.5% TDS will be worn for 14 days
Study NCT03248440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TDS
Description: No active substance; Placebo TDS will be worn each day for 14 days
Study NCT01987375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: a single dose of the study drug following a single loading dose of unlabeled cetuximab
Study NCT03255941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
Study NCT03255941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sayana Press
Description: The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
Study NCT01052662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 30mg/day Memantine orally everyday for 12 weeks
Study NCT01052662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 15 mg/day Memantine orally everyday for 12 weeks
Study NCT01052662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally everyday for 12 weeks
Study NCT03070314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinaforce junior
Description: Echinacea Purpurea Extract Pill, sweetened and with orange flavour
Study NCT01071889 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Flumazenil
Description: Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
Study NCT01071889 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo - only excipients with no API
Study NCT00372060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
Study NCT00372060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: sitagliptin phosphate (MK0431)
Description: Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
Study NCT00372060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: pioglitazone
Description: pioglitazone once daily for 52 weeks
Study NCT00372060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone once daily for 52 weeks
Study NCT00372060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Placebo once daily for 12 weeks
Study NCT01148043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg capsule, 2 capsules QD for 24 weeks.
Study NCT01148043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: capsule, 2 capsules QD for 24 weeks
Study NCT03198260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial manipulation
Description: Deep frictional massage
Study NCT03198260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascial manipulation
Description: Deep frictional massage
Study NCT02278575 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atenativ
Description: intravenous transfusion
Study NCT01680120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia
Description: Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.~Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.~Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12).
Study NCT01579578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: 40 mg, oral dose twice daily
Study NCT01579578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral dose twice daily
Study NCT01579578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV once weekly for 3 weeks followed by a week off.
Study NCT01579578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV once weekly for 3 weeks followed by a week off.
Study NCT02920593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D prophylaxis
Study NCT05058586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Effects of Aerobic Exercise Training on Cardiorespiratory Fitness, Functional Capacity, Balance and Ventricular Repolarization Indices in Stroke Patients
Description: Seventy patients with history of stroke admitted to our center between July 2017 and January 2018. Subjects participated in the study were randomly assigned to anti-gravity treadmill training, underwater walking therapy and control group. We examined aerobic capacity of participants by using 6-minute walk test and cycle ergometer testing before starting the treatment along with one month follow up. Patient's balance examined by using the Berg Balance Scale (BBS).
Study NCT00918749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg
Description: 150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
Study NCT00918749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg
Description: 75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
Study NCT00918749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg
Description: 100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
Study NCT02572206 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: PET/SPECT Scan
Description: PET scan will be performed on a mCT scanner.
Study NCT02572206 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Structural MRI will be obtained to permit co-registration of PET images.
Study NCT01266148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
Study NCT01266148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
Study NCT01266148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
Study NCT01266148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
Study NCT01266148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Thymocyte Globulin
Description: Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
Study NCT04389606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Formula (SF)
Description: New infant formula for term infants fed ad lib
Study NCT04389606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Formula (SF)
Description: New infant formula for term infants fed ad lib
Study NCT04389606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Formula (CF)
Description: Commercially available infant formula for term infants fed ad lib
Study NCT01337271 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBT - NAVA
Description: An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
Study NCT04389606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator Formula (CF)
Description: Commercially available infant formula for term infants fed ad lib
Study NCT02575794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terameprocol
Description: Given PO
Study NCT02575794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02547077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Closure with 2-octylcyanoacrylate
Study NCT02547077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with 2-octylcyanoacrylate
Study NCT01642134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin+clopidogrel (Duoplavin)
Description: 100 mg aspirin ;75 mg clopidogrel 3º months
Study NCT02547077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound Closure with 5-0 Fast Absorbing Gut Sutures
Study NCT02547077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Closure with 5-0 Fast Absorbing Gut Sutures
Study NCT01445743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Tdap Vaccine
Description: Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
Study NCT01642134 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: aspirin+clopidogrel (Duoplavin)
Description: 100 mg aspirin ;75 mg clopidogrel 3º months
Study NCT00401817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg on day 1 of each of 6 cycles
Study NCT01445743 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Biological/Vaccine: Tdap Vaccine
Description: Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
Study NCT00401817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2
Study NCT00401817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
Study NCT02015663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
Study NCT02015663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
Study NCT02306395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial local injury
Description: The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
Study NCT03688542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Circle Deprescribing Module
Description: The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
Study NCT03018106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene
Description: Ospemifene is a selective estrogen receptor modulator (SERM), and it is the only SERM approved in the United States to treat moderate to severe dyspareunia associated with VVA. It is an oral medication that is taken as a 60mg tablet once daily. Food intake increases its absorption by 2 to 3-fold, and this is not impacted by the fat or calorie content of the food. It is metabolized primarily in the liver, and is excreted in feces.
Study NCT03018106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal conjugated estrogens
Description: Conjugated estrogens are a mixture of several different estrogen salts derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate. Vaginal estrogen is considered the medication of choice for treating vulvovaginal atrophy (VVA).
Study NCT01113463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Starting dose of 160 mg/m\^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
Study NCT00136916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin
Description: Inhaled insulin with dose adjusted according to premeal blood glucose
Study NCT00136916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous insulin
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Study NCT03551353 — intervention group
Intervention type: OTHER
Intervention: Group before Video-assisted feedback
Description: Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
Study NCT03510858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multilevel training intervention (intervention group)
Description: QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.
Study NCT03510858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multilevel training intervention (control group with crossover)
Description: The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
Study NCT03551353 — intervention group
Intervention type: OTHER
Intervention: Group after Video-assisted feedback
Description: Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
Study NCT00494845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: 8-week mindfulness program will be compared to an education control group.
Study NCT00494845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: Health Education Class
Description: 8-week education program
Study NCT02571400 — intervention group
Intervention type: OTHER
Intervention: Continued use of opioid analgesics >90 days post-surgery
Description: Exposure of interest: continued use of opioid analgesics >90 days post-surgery
Study NCT00589784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
Study NCT03986632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tundra Gifts
Description: Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.